Vilin Bio Med
VILINBIO NSE
Vilin Bio Med
HealthcareNSE: VILINBIO Pharmaceuticals & Biotechnology
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹89.90 Cr
Volatility
High Risk
P/E Ratio
46.8
EBITDA
₹3.19 Cr
Return on Equity
0.97%
Debt to Equity
0.01
Book Value
₹18.6
52W High
₹60.95
52W Low
₹18.95
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has reduced debt.
- Company is almost debt free.
Weaknesses
4- Stock is trading at 3.17 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -2.92%
- Company has a low return on equity of 3.53% over last 3 years.
Growth Rate
Revenue Growth
176% higher than
3Y
Net Income Growth
880% higher than
3Y
Cash Flow Change
103% lower than
3Y
ROE
36.62% higher than
3Y
ROCE
13.73% higher than
3Y
EBITDA Margin (Avg.)
-8.15% lower than
3Y
Quarterly Results
| Particulars | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.95 | 4.1 | 8.21 | 7.65 | 8.16 | 4.49 | 10.32 | 9.66 | 32.6 |
| Expenses | 4.56 | 2.99 | 6.74 | 6.26 | 8.73 | 4.07 | 9.95 | 9.32 | 29.74 |
| Operating Profit | 0.39 | 1.11 | 1.47 | 1.39 | -0.57 | 0.42 | 0.37 | 0.34 | 2.86 |
| OPM % | 7.88% | 27.07% | 17.9% | 18.17% | -6.99% | 9.35% | 3.59% | 3.52% | 8.77% |
| Other Income | 0 | 0 | 0.02 | 0.11 | 0.22 | 0.22 | 0.25 | 0 | 0 |
| Interest | 0.25 | 0.32 | 0.33 | 0.38 | 0.41 | 0.41 | 0.44 | 0.07 | 0 |
| Depreciation | 0.11 | 0.08 | 0.08 | 0.08 | 0.05 | 0.07 | 0.03 | 0.07 | 0.21 |
| PBT | 0.03 | 0.71 | 1.08 | 1.04 | -0.81 | 0.16 | 0.15 | 0.2 | 2.65 |
| Tax % | 33.33% | 21.13% | 35.19% | 25.96% | -25.93% | 18.75% | 33.33% | 25% | 32.83% |
| Net Profit | 0.02 | 0.55 | 0.69 | 0.77 | -0.61 | 0.12 | 0.1 | 0.15 | 1.78 |
| EPS in Rs | 0.06 | 1.67 | 0.69 | 0.55 | -0.44 | 0.09 | 0.07 | 0.11 | 1.17 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 16.62 | 11.54 | 11.21 | 12.31 | 15.8 | 14.81 | 42.26 |
| Expenses | 15.71 | 10.68 | 10.44 | 9.73 | 14.97 | 14.02 | 39.06 |
| Operating Profit | 0.91 | 0.86 | 0.77 | 2.58 | 0.83 | 0.79 | 3.2 |
| OPM % | 5.48% | 7.45% | 6.87% | 20.96% | 5.25% | 5.33% | 7.57% |
| Other Income | 0.01 | 0 | 0 | 0.02 | 0.32 | 0.47 | 0 |
| Interest | 0.41 | 0.44 | 0.51 | 0.65 | 0.79 | 0.85 | 0.07 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.17 | 0.13 | 0.1 | 0.28 |
| PBT | 0.2 | 0.16 | 0.04 | 1.78 | 0.23 | 0.31 | 2.85 |
| Tax % | 20% | 25% | 25% | 30.34% | 26.09% | 25.81% | 31.93% |
| Net Profit | 0.16 | 0.12 | 0.03 | 1.25 | 0.16 | 0.22 | 1.93 |
| EPS in Rs | 0.48 | 0.36 | 0.09 | 1.26 | 0.11 | 0.16 | 1.27 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3.3 | 3.3 | 3.3 | 9.95 | 13.95 | 13.95 | 15.25 |
| Reserves | 3.94 | 4.06 | 4.1 | 0.73 | 8.89 | 9.11 | 13.12 |
| Borrowings | 4.53 | 5.52 | 5.3 | 4.93 | 6.83 | 2.57 | 0.21 |
| Other Liabilities | 2.24 | 1.01 | 0.86 | 2.07 | 2.73 | 2.1 | 6.36 |
| Total Liabilities | 14.01 | 13.89 | 13.56 | 17.68 | 32.4 | 27.73 | 34.94 |
| Fixed Assets | 2.13 | 1.87 | 1.65 | 1.51 | 1.38 | 1.28 | 2.87 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1.57 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 11.88 | 12.02 | 11.91 | 16.17 | 31.02 | 24.88 | 32.07 |
| Total Assets | 14.01 | 13.89 | 13.56 | 17.68 | 32.4 | 27.73 | 34.94 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | -1.46 | -1 | 0.21 | -1.66 | -7.42 | 0.22 | 0.7 |
| Investing | -0.02 | 0 | 0 | -0.03 | 0.32 | -1.11 | -0.3 |
| Financing | 1.51 | 0.98 | -0.22 | 1.68 | 8.87 | -5.1 | 1.01 |
| Net Cash Flow | 0.03 | -0.02 | -0.01 | 0 | 1.77 | -5.99 | 1.41 |
| Free Cash Flow | -1.48 | -1 | 0.21 | -1.69 | -7.42 | -1.35 | 0.4 |
| CFO/OP | -156 | -112 | 29 | -43 | -888 | 37 | 49 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 160 | 242 | 254 | 166 | 131 | 156 | 138 |
| Inventory Days | 56.13 | 83.17 | 93.82 | 44.74 | 125 | 120 | 70.03 |
| Days Payable | 49.48 | 33.11 | 26.34 | 60.49 | 54.71 | 37.67 | 32.49 |
| Cash Conversion Cycle | 166 | 292 | 321 | 150 | 202 | 237 | 175 |
| Working Capital Days | 111 | 204 | 212 | 45.07 | 76.23 | 195 | 168 |
| ROCE % | — | 4.87% | 4.3% | 17.17% | 4.51% | 4.2% | 10.77% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vilin Bio Med insights
29 extracted metrics + investor summaries across FY20–FY26.
Documents
1
Amalgamation/Merger
11 Sep - NCLT allowed Chemgenix-Vilin amalgamation application; meetings of creditors/public shareholders fixed for 15 Oct 2026. 11 Sep - NCLT allowed Chemgenix-Vilin amalgamation application; meetings of creditors/public shareholders fixed for 15 Oct 2026.
2
Shareholders meeting
3 Sep - 20th AGM held September 2, 2026; all nine resolutions passed with requisite majority. 3 Sep - 20th AGM held September 2, 2026; all nine resolutions passed with requisite majority.
3
Shareholders meeting
3 Sep - 20th AGM voting results filed; all 9 resolutions passed on September 2, 2026. 3 Sep - 20th AGM voting results filed; all 9 resolutions passed on September 2, 2026.
4
Shareholders meeting
2 Sep - 20th AGM held on 2 Sep 2026; FY26 accounts, director reappointment and borrowing approvals considered. 2 Sep - 20th AGM held on 2 Sep 2026; FY26 accounts, director reappointment and borrowing approvals considered.
5
Copy of Newspaper Publication
13 Aug - Published newspaper ads for notice of Vilin Bio Med's 20th Annual General Meeting on August 13, 2026. 13 Aug - Published newspaper ads for notice of Vilin Bio Med's 20th Annual General Meeting on August 13, 2026.
Frequently Asked Questions about Vilin Bio Med
What does Vilin Bio Med Ltd do?
Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products[1]
Where is Vilin Bio Med Ltd (VILINBIO) listed?
Vilin Bio Med Ltd trades as VILINBIO on the NSE.
Which sector does Vilin Bio Med Ltd belong to?
Vilin Bio Med Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Vilin Bio Med Ltd?
Vilin Bio Med Ltd has a market capitalisation of ₹89.9 Cr, which places it in the Small Cap band.
What is the PE ratio of Vilin Bio Med Ltd?
Vilin Bio Med Ltd trades at a PE ratio of 46.80, against a book value of ₹18.6 per share.
What is the 52-week high and low of Vilin Bio Med Ltd?
Over the last 52 weeks Vilin Bio Med Ltd has traded between ₹18.95 and ₹60.95.
What is the Return on Equity (ROE) of Vilin Bio Med Ltd?
Vilin Bio Med Ltd reported a return on equity of 0.97%. Its debt-to-equity ratio is 0.01.
Company Information
Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VILINBIO.md for Vilin Bio Med Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.